Statistics Collaborative - Design and analysis for biomedical research

Therapeutic AreasTherapeutic Areas


With the growing worldwide epidemic of Type 2 diabetes, and the high prevalence of Type 1 diabetes, the pharmaceutical industry is developing a variety of new drugs for prevention and treatment.

We at Statistics Collaborative, Inc. (SCI), and especially our senior staff, have been involved in trials of diabetes since our founding in 1990. We have worked with pharmaceutical companies to summarize epidemiologic data on the emergence of complications. Senior staff members have served on the Data Monitoring Committees (DMCs) for some major randomized trials of interventions to prevent diabetes conducted by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). We have served on review teams established by the NIDDK to evaluate statistical centers for diabetes networks and to discuss which direction the Institute should take in allocating its resources for diabetes research.

Examples of SCI’s work in diabetes:

  • Diabetic retinopathy: Drawing on its experience in ophthalmology, SCI prepared interim safety reports for trials investigating interventions for the ophthalmologic sequelae of diabetes.
  • Novel treatments of diabetes: SCI has worked with companies that are developing biologics for treatment of Type 1 diabetes and companies that are studying possible cardiovascular sequelae of treatments for Type 2 diabetes.
  • Comparison of insulins: SCI has been involved in several studies comparing different types of insulins for both Type 1 and Type 2 diabetes. The trials have compared insulins with respect to their effect on HbAlc and other outcomes that measure efficacy, as well as their safety as measured primarily by their frequency of hypoglycemic episodes associated with their use.